Campanile, A.; Visco, V.; De Carlo, S.; Ferruzzi, G.J.; Mancusi, C.; Izzo, C.; Mongiello, F.; Di Pietro, P.; Virtuoso, N.; Ravera, A.;
et al. Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients. Life 2023, 13, 1174.
https://doi.org/10.3390/life13051174
AMA Style
Campanile A, Visco V, De Carlo S, Ferruzzi GJ, Mancusi C, Izzo C, Mongiello F, Di Pietro P, Virtuoso N, Ravera A,
et al. Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients. Life. 2023; 13(5):1174.
https://doi.org/10.3390/life13051174
Chicago/Turabian Style
Campanile, Alfonso, Valeria Visco, Stefania De Carlo, Germano Junior Ferruzzi, Costantino Mancusi, Carmine Izzo, Felice Mongiello, Paola Di Pietro, Nicola Virtuoso, Amelia Ravera,
and et al. 2023. "Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients" Life 13, no. 5: 1174.
https://doi.org/10.3390/life13051174
APA Style
Campanile, A., Visco, V., De Carlo, S., Ferruzzi, G. J., Mancusi, C., Izzo, C., Mongiello, F., Di Pietro, P., Virtuoso, N., Ravera, A., Bonadies, D., Vecchione, C., & Ciccarelli, M.
(2023). Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients. Life, 13(5), 1174.
https://doi.org/10.3390/life13051174
